ArticleBMC endocrine disorders2025
Serum CA 19 - 9 and CA 72 - 4 levels in hashimoto's thyroiditis: a prospective case-control study.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHashimoto's thyroiditis is a common autoimmune thyroid disorder and a leading cause of subclinical hypothyroidism. Tumor markers such as CA 19 - 9 and CA 72 - 4 may also be elevated in certain benign inflammatory conditions. This study aimed to investigate the levels of CA 19 - 9 and CA 72 - 4 in patients with subclinical hypothyroidism due to Hashimoto's thyroiditis and to evaluate the effects of levothyroxine treatment.
methodsThis prospective case-control study included 30 patients with subclinical hypothyroidism due to Hashimoto's thyroiditis and 30 healthy controls matched by age and sex. Serum levels of CA 19 - 9, CA 72 - 4, TSH, free T4, TPOAb, and TgAb were measured at baseline and after 6 weeks of levothyroxine therapy. Additionally, correlations between tumor markers and thyroid function parameters were analyzed.
resultsInitially, there were no significant differences in CA 19 - 9 and CA 72 - 4 levels between the patient and control groups. Following treatment, a significant decrease in CA 19 - 9 levels was observed in patients who achieved euthyroidism (p = 0.020), whereas no significant change was detected in CA 72 - 4 levels.
conclusionsCA 19 - 9 and CA 72 - 4 levels do not appear to differ significantly between patients with subclinical hypothyroidism due to Hashimoto's thyroiditis and healthy individuals. However, CA 19 - 9 levels may decrease upon restoration of euthyroidism, potentially reflecting a reduction in thyroid-related inflammation. Further studies with larger cohorts and longer follow-up periods are warranted to confirm and clarify these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.